Literature DB >> 1714022

Nebivolol induces endothelium-dependent relaxations of canine coronary arteries.

Y S Gao1, T Nagao, R A Bond, W J Janssens, P M Vanhoutte.   

Abstract

Nebivolol is a new beta 1-antagonist that acutely reduces arterial blood pressure without depressing cardiac function. The present study was designed to determine the effect of nebivolol on coronary arteries. Rings of canine left anterior descending coronary (LAD) artery with or without endothelium were suspended in organ chambers and the isometric tension was recorded. In some experiments, the transmembrane potential of the smooth muscle cells was recorded by electrophysiological methods. During contractions to prostaglandin F2 alpha, nebivolol induced concentration-dependent relaxations of the coronary arteries. The enantiomer, l-nebivolol, also induced comparable relaxations; however, d-nebivolol induced smaller relaxations. The relaxations induced by nebivolol and its enantiomer were significantly larger in tissues with than in those without endothelium. The differences between tissues with and without endothelium were abolished by nitro-L-arginine (3 x 10(-5) M) or methylene blue (10(-5) M). The nebivolol-induced relaxations were not affected by indomethacin (10(-5) M), phentolamine (5 x 10(-6) M), propranolol (5 x 10(-6) M), or methysergide (3 x 10(-6) M). Nebivolol at a subthreshold concentration for inducing relaxation (3 x 10(-7) M) did not significantly affect endothelium-dependent relaxations to acetylcholine but potentiated ADP-induced endothelium-dependent relaxations. The potentiation is stereoselective for l-nebivolol. Nebivolol induced a small hyperpolarization of the coronary smooth muscle with endothelium (1 mV).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714022     DOI: 10.1097/00005344-199106000-00016

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  26 in total

Review 1.  Effects of antihypertensive drugs on endothelial dysfunction: clinical implications.

Authors:  Stefano Taddei; Agostino Virdis; Lorenzo Ghiadoni; Isabella Sudano; Antonio Salvetti
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Pharmacological properties of nebivolol in man.

Authors:  L M Van Bortel; J N de Hoon; M J Kool; J A Wijnen; C I Vertommen; L G Van Nueten
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

3.  Hypertension treatment in the Asia-Pacific: the role of and treatment strategies with nebivolol.

Authors:  Cheol-Ho Kim; Nelson Abelardo; Peera Buranakitjaroen; Rungroj Krittayaphong; Chin Hock Lim; Sung-Ha Park; Nguyen Vinh Pham; Gregorio Rogelio; Bernard Wong; Lip Ping Low
Journal:  Heart Asia       Date:  2016-02-24

Review 4.  Treating coronary disease and the impact of endothelial dysfunction.

Authors:  Yasushi Matsuzawa; Raviteja R Guddeti; Taek-Geun Kwon; Lilach O Lerman; Amir Lerman
Journal:  Prog Cardiovasc Dis       Date:  2014-10-22       Impact factor: 8.194

5.  Protective effects of Nebivolol against interleukin-1β (IL-1β)-induced type II collagen destruction mediated by matrix metalloproteinase-13 (MMP-13).

Authors:  Zhigang Li; Baoyi Liu; Dewei Zhao; BenJie Wang; Yupeng Liu; Yao Zhang; Fengde Tian; Borui Li
Journal:  Cell Stress Chaperones       Date:  2017-05-17       Impact factor: 3.667

6.  Calmidazolium, a calmodulin inhibitor, inhibits endothelium-dependent relaxations resistant to nitro-L-arginine in the canine coronary artery.

Authors:  S Illiano; T Nagao; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

7.  Investigation of the different adrenoceptor targets of nebivolol enantiomers in rat thoracic aorta.

Authors:  T Tran Quang; B Rozec; L Audigane; C Gauthier
Journal:  Br J Pharmacol       Date:  2009-02-04       Impact factor: 8.739

8.  Simultaneous Estimation of Nebivolol Hydrochloride and Valsartan using RP HPLC.

Authors:  S U Kokil; M S Bhatia
Journal:  Indian J Pharm Sci       Date:  2009-03       Impact factor: 0.975

9.  Nitric oxide proxies and ocular perfusion pressure in primary open angle glaucoma.

Authors:  F Galassi; G Renieri; A Sodi; F Ucci; L Vannozzi; E Masini
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

10.  Enhancement of arterial relaxation by long-term atenolol treatment in spontaneously hypertensive rats.

Authors:  M Kähönen; H Mäkynen; P Arvola; I Pörsti
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.